Published on : Apr 16, 2018
Albany, New York, April 16, 2018: Diabetic retinopathy is the most common eye disease associated with diabetes and it's the leading cause of blindness among working-age people. A new research, titled “Proliferative Diabetic Retinopathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2026” has been freshly publicized to the wide database of Market Research Hub (MRH), which offers a comprehensive analysis of the current market trends and future estimations in the market. Moreover, the report covers market dynamics including drivers, restraints opportunities, and trends expected to influence the global proliferative diabetic retinopathy market growth during the said period.
Among complications of diabetic retinopathy, proliferative diabetic retinopathy has witnessed a relatively more significant surge worldwide. The extremity of the disease, regulates the selection of effective therapeutic measure, thereby involving requirement for intraocular injections, laser surgery, vitrectomy, or anti-VEGF drug prescriptions. Considering this, remarkable advancements have been made in the diagnosis and treatment of the disease. This 170-page study offers extensive analysis on the development of market and predicts where the market stands to gain in future.
Growth prospects offered in the report are assessed for the period between 2017 and 2026. According to the research key findings, the global market for proliferative diabetic retinopathy to register a high splendid CAGR of 9.5% through the forecast period (2017-2026). Nearly US$ 1,000 Mn worth of drugs for the treatment of proliferative diabetic retinopathy are projected to be sold worldwide by 2026-end.
In order to provide a comprehensive view of the market, the proliferative diabetic retinopathy market has been segmented on the basis of drug class, mode of administration, distribution channel and geography. Geographically, the market spread has been analyzed in major regions including North America, Middle East & Africa (MEA), Japan, Europe, the Asia Pacific excluding Japan, and Latin America; the regions are analyzed in terms of revenue and volume generation along with the CAGR for the period from 2015 to 2025. As reported, North America is likely to remain at the forefront of the global proliferative diabetic retinopathy in terms of revenue, driven by supportive reimbursement policies offered by the government.
On the basis of drug class, the research finds that anti-VEGF drugs are likely to remain chosen among various drug class utilized for treatment of proliferative diabetic retinopathy across the globe. By mode of administration, the study covers injectable, oral and others. Out of these two, Albeit injectables will account for relatively larger market revenue share in the coming years.
As the report moves ahead, the report also encompasses an exhaustive chapter on the proliferative diabetic retinopathy market’s competitive landscape, which gives a detailed profiling of key companies that offer the significant contribution to the market growth. Some of them are Genentech, Inc. (Roche Holdings), Merck KGaA, Allergan Plc., Pfizer, Inc., Cipla, Ltd., Valeant Pharmaceuticals International, Inc., Intas Pharmaceuticals Limited, and Novartis AG.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1701738
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org